Novartis Drops Patent Claims Against Ranbaxy

Law360, New York (September 21, 2007, 12:00 AM EDT) -- Pharmaceutical company Novartis International AG has indicated that it is dropping its patent claims against Ranbaxy Laboratories Limited over the top-selling hypertension drug Diovan.

In papers filed in the U.S. District Court for the District of New Jersey, Novartis said that it will dismiss its patent claims against Ranbaxy, because the generic drug maker had amended its abbreviated new drug application with the U.S. Food and Drug Administration, converting its paragraph IV certification to a paragraph III certification.

The effect of this conversion is that Ranbaxy...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.